LCMS-Based Metabolic Analysis Explores the Effect of American Ginseng on Urine and Plasma in Healthy Individuals
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: American Gginseng.
- Who it may be relevant to
- Registry conditions: The Impact of American Ginseng on the Metabolomics of Urine and Plasma in Healthy Individuals. Basic parameters: 18 years — 45 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Researchers will use LCMS Metabolic Analysis to Explore the Effect of American Ginseng on Urine and Plasma in Healthy Individuals Participants will: * Take 3 grams of American Ginseng powder every day for 14 days * Collect the fasting urine samples at the following times at the hospital: On the first day, on the 7th day after taking the medicine, and on the 14th day after taking the medicine. * Collect the fasting Serum samples at the following times at the hospital: On the first day and on the 14th day after taking the medicine. * Have their any adverse effects monitored and evaluated throughout the study.
Interventions
- Other American Gginseng
All the subjects took 3 grams of ginseng half an hour after breakfast every day for 14 consecutive days.
Primary outcome measures
- Urine metabolomics [Time frame: From enrollment to the end of treatment at 2 weeks]
Secondary outcome measures (1)
- Plasma metabolomics [Time frame: From enrollment to the end of treatment at 2 weeks]
Eligibility criteria
- 18 to 45 years old;
- The subjects were fully informed about the research process and signed the informed consent form (the subjects had no abnormalities in routine physical examinations, no previous medical history, and no history of drug allergies); ③ During the trial, they were required to have a light diet and were prohibited from consuming alcoholic and caffeinated beverages;
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Other
Study locations
China · 1 center
- Zhejiang Cancer Hospital — Hangzhou
Identifiers
NCT: NCT07252362 · 2021KY577